Abstract
Objectives Pediatric SARS-CoV-2 data remain limited and seropositivity rates in children were reported as <1% early in the pandemic. Seroepidemiologic evaluation of SARS-CoV-2 in children in a major metropolitan region of the United States was performed.
Methods Children and adolescents ≤19 years were enrolled in a cross-sectional, observational study of SARS-CoV-2 seroprevalence from July-October 2020 in Northern Virginia, United States. Demographic, health, and COVID-19 exposure information was collected, and blood was analyzed for SARS-CoV-2 spike protein total antibody. Risk factors associated with SARS-CoV-2 seropositivity were analyzed. Orthogonal antibody testing was performed, and samples were evaluated for responses to different antigens.
Results In 1038 children, the anti-SARS-CoV-2 total antibody positivity rate was 8.5%. After multivariate logistic regression, significant risk factors included Hispanic ethnicity, public or absent insurance, a history of COVID-19 symptoms, exposure to person with COVID-19, a household member positive for SARS-CoV-2 and multi-family or apartment dwelling without a private entrance. 66% of seropositive children had no symptoms of COVID-19. Orthogonal antibody testing with a receptor binding domain specific antigen revealed a high concordance of 80.5%. Children also demonstrated a robust immune response to the nucleocapsid antigen.
Conclusions A much higher burden of SARS-CoV-2 infection, as determined by seropositivity, was found in children than previously reported; this was also higher compared to adults in the same region at a similar time. Contrary to prior reports, we determined children shoulder a significant burden of COVID-19 infection. The role of children’s disease transmission must be considered in COVID-19 mitigation strategies including vaccination.
Article Summary 8.5% of children had SARS-CoV-2 antibodies in Fall 2020, double the adult rate. The role of pediatric infection is important to consider in mitigation strategies.
What’s Known on This Subject SARS-CoV-2 pediatric seroepidemiologic data is limited. Reported viral rates underestimate the burden of infection in children due to mild or asymptomatic disease. Limited cohorts of children suggest low seropositivity rates compared to adults.
What This Study Adds US children in the largest SARS-CoV-2 seroepidemiology study to date had double the rate of antibodies compared to adults. Most children were asymptomatic. Risk factors include age, ethnicity and living conditions. Most children made antibodies to different antigens of SARS-CoV-2.
Competing Interest Statement
Author Christopher Defillipi consults for Ortho Diagnostics, Abbott Diagnostics, and Siemens Healthineers. No other authors have any financial or personal conflicts of interest to disclose.
Funding Statement
The Virginia Department of Health provided funding for this study. The Virginia Department of Health, in conjunction with the authors of this manuscript, were involved in study design, the writing of the report and the decision to submit the paper for publication. The Virginia Department of Health were not involved in collection, analysis or interpretation of the data. Research reported in this publication was also supported in part by the National Institute of Child Health and Human Development under Award Number K23HD099240 (Hourigan). Research reported in this publication was also supported in part via a subcontract from the parent award by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR003015 (Hunter, Sun, Bruce). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Inova Health Systems Human Research Protection Office waived ethics approval as per CFR 45 46.102, as this project was a public health surveillance activity, funded by the Virginia Department of Health (VDH).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Disclosures: Author Christopher Defillipi consults for Ortho Diagnostics, Abbott Diagnostics, and Siemens Healthineers. No other authors have any conflicts of interest relevant to this article to disclose.
Funding/Support and Role of Funder: The Virginia Department of Health provided funding for this study. The Virginia Department of Health, in conjunction with the authors of this manuscript, were involved in study design, the writing of the report and the decision to submit the paper for publication. The Virginia Department of Health were not involved in collection, analysis or interpretation of the data. Research reported in this publication was also supported in part by the National Institute of Child Health and Human Development under Award Number K23HD099240 (Hourigan). Research reported in this publication was also supported in part via a subcontract from the parent award by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR003015 (Hunter, Sun, Bruce). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Data Availability
Data sharing requests will be considered by the authors upon written request to the corresponding author. Deidentified participant data or other prespecified data will be available subject to a written proposal and a signed data sharing agreement.
